New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
Michele Ghidini,1 Jens Claus Hahne,2 Francesco Trevisani,3 Stefano Panni,1 Margherita Ratti,1 Laura Toppo,1 Gianluca Tomasello1 1Medical Department, Division of Oncology, ASST di Cremona, Ospedale di Cremona, Cremona, Italy; 2Division of Molecular Pathology, The Institute of Cancer Research, London...
Main Authors: | Ghidini M, Hahne JC, Trevisani F, Panni S, Ratti M, Toppo L, Tomasello G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-06-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/new-developments-in-the-treatment-of-chemotherapy-induced-neutropenia--peer-reviewed-article-TCRM |
Similar Items
-
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety
by: Reshma Mahtani, et al.
Published: (2021-05-01) -
Prevention of febrile neutropenia in oncological patients: real-world data
by: Kirill V. Sapozhnikov, et al.
Published: (2023-05-01) -
Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage
by: Jeffrey Crawford, et al.
Published: (2021-01-01) -
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
by: Esse I. H. Akpo, et al.
Published: (2017-09-01) -
Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)